f Post-Approval Studies (PAS) Database
Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS) Database
  • Print
  • Share
  • E-mail
-

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


           

Histological and Retrieval Analysis PAS


Suggest Enhancement / Report Issue | export reports to excelExport to Excel
General
Study Status Ongoing
Application Number /
Requirement Number		 P160050 / PAS002
Date Original Protocol Accepted 05/07/2019
Date Current Protocol Accepted 05/19/2020
Study Name Histological and Retrieval Analysis PAS
Device Name BARRICAID ANULAR CLOSURE DEVICE (ACD)
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group No Control
Analysis Type Descriptive
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Objectives The purpose of this post-approval evaluation is to investigate potential underlying mechanisms that may contribute to endplate lesion (EPL) initiation and/or growth through retrieval analysis and histological analysis of retrieved implants and/or peri-prosthetic tissue. This study is also intended to evaluate causes of device failure (fracture, migration, dissociation and wear particulate). Analysis of tissue and devices/material from retrieved (explanted) Barricaid® ACDs that were originally implanted following discectomy in real-world (i.e., commercial, not clinical study) experience.
Study Population All patients implanted with a Barricaid® ACD in the United States.
Sample Size This evaluation is not powered to demonstrate statistical conclusions, but rather to gather data for subsequent analysis and surveillance.
Key Study Endpoints Histological analysis of tissue and explant material will be assessed per ASTM F561-13.
Follow-up Visits and Length of Follow-up This evaluation shall remain in place for 5 years


Histological and Retrieval Analysis PAS Reporting Schedule

Reporting Schedule
Report
Date Due
FDA Receipt
Date
Applicant's Reporting Status
6 month report 08/09/2019 09/18/2019 Overdue/Received
1 year report 02/08/2020 02/10/2020 Overdue/Received
18 month report 08/08/2020 08/06/2020 On Time
2 year report 02/07/2021 02/08/2021 Overdue/Received
3 year report 02/07/2022 02/08/2022 Overdue/Received
4 year report 02/07/2023 02/07/2023 On Time
5 year report 02/07/2024 02/07/2024 On Time
6 year report 02/07/2025    


Contact Us
Mandated Studies Program
Food and Drug Administration
10903 New Hampshire Ave.
Silver Spring, MD 20993-0002
Email: MandatedStudiesPrograms@fda.hhs.gov

Additional Resources

-
-